This article was originally published in The Gray Sheet
Executive SummarySigns memorandum of understanding giving Nihon Medi-Physics exclusive Japanese distribution rights to Spectral's cardiac panel tests. The Japanese firm will make an up-front payment of $300,000, with additional payments totaling $1.2 mil. to be made "upon achievement of certain milestones." Spectral signed a deal last year giving Baxter exclusive distribution rights in North and South America and Europe for some of Spectral's cardiac tests ("The Gray Sheet" Sept. 6, ln Brief)
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.